GLAXO — GlaxoSmithKline Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for GlaxoSmithKline Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	32,244	29,256	32,780	32,517	34,537
Cost of Revenue
Gross Profit	17,897	15,576	17,959	18,574	19,966
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	35,257	25,804	25,990	25,139	27,780
Operating Profit	-3,014	3,452	6,790	7,378	6,757
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,058	4,540	7,790	8,364	8,162
Provision for Income Taxes
Net Income After Taxes	1,101	2,873	3,808	6,076	5,900
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	932	3,581	16,947	6,107	5,900
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	932	3,581	16,947	6,107	5,900
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	19.5	23.4	22.1	35.9	40.9
Dividends per Share
Special Dividends per Share